

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 29, 2022 (the “**Prospectus**”) issued by MicroPort NeuroTech Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time (the “**U.S. Securities Act**”). The securities mentioned herein may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities by the Company in the United States.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

STABILIZING ACTIONS, END OF STABILIZING PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZING PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilizing period in connection with the Global Offering ended on Sunday, August 7, 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of the stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, as the Stabilizing Manager, or any person acting for it, during the stabilizing period is set out in this announcement.

LAPSE OF THE OVER-ALLOTMENT OPTION

The Joint Global Coordinators (on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilizing period and the Over-allotment Option lapsed on Sunday, August 7, 2022.

STABILIZING ACTIONS AND END OF STABILIZING PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company hereby announces that the stabilizing period in connection with the Global Offering ended on Sunday, August 7, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. China International Capital Corporation Hong Kong Securities Limited, as the Stabilizing Manager, or any person acting for it, has undertaken the following stabilizing actions during the stabilizing period:

- (1) over-allocation of an aggregate of 2,055,000 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) borrowing of an aggregate of 2,055,000 Shares by the Stabilizing Manager from MP Scientific pursuant to the Stock Borrowing Agreement to cover over-allocations in the International Offering. Such Shares will be returned and redelivered to MP Scientific in accordance with the terms of the Stock Borrowing Agreement;
- (3) the successive purchases of an aggregate of 2,055,000 Shares in the price range of HK\$24.30 to HK\$24.60 per Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) on the market during the stabilizing period, representing approximately 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to facilitate the return of 2,055,000 Shares borrowed from MP Scientific pursuant to the Stock Borrowing Agreement; and
- (4) the last purchase made by the Stabilizing Manager, or any person acting for it, on the market during the stabilizing period was on Monday, July 18, 2022, at the price of HK\$24.30 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%).

LAPSE OF THE OVER-ALLOTMENT OPTION

The Joint Global Coordinators (on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilizing period and the Over-allotment Option lapsed on Sunday, August 7, 2022.

PUBLIC FLOAT

Immediately after the end of the stabilizing period, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) of the Listing Rules.

By order of the Board of Directors
MicroPort NeuroTech Limited
微創腦科學有限公司
Mr. Peng Bo
Chairman

Hong Kong, August 7, 2022

As at the date of this announcement, the executive Directors are Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce, the non-executive Directors are Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia, and the independent non-executive Directors are Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung.